Rete Oncologica Campana – Napoli 17 maggio 2018

RELATORI

amEnrico Coscioni, Consigliere del Presidente della Regione
Campania per la Sanità

Enrico Coscioni è nato nel 1961. Dopo essersi laureato in Medicina e Chirurgia nel 1987, si è specializzato in Cardiochirurgia nel 1993 ed in Chirurgia Toracica nel 1998. Negli anni 1991-1992 ha svolto attività di ricerca clinica presso la Stanford University, California. Nel 2006 ha conseguito un Corso di Formazione Manageriale per Cardiochirurghi presso l’Università LUISS Guido Carli. Ad oggi è Responsabile di Unità Operativa Complessa di Cardiochirurgia presso l’Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi D’Aragona a Salerno. In merito alla sua attività di ricerca, è autore di numerose pubblicazioni nazionali ed internazionali, oltre a vantare numerosissime partecipazioni a congressi sia nazionali che internazionali in qualità di relatore. Da Novembre 2016 è referente dei rapporti istituzionali per la Società Italiana di Chirurgia Cardiaca (SICCH). Per quanto concerne la sua attività didattica, dal 2011 è docente a contratto presso il Dipartimento di Medicina e Chirurgia dell’Università degli Studi di Salerno. In merito alla sua attività politico-sanitaria, dal 2014 è consigliere del presidente della Regione Campania per la Sanità. Inoltre, dal 2017 è Vice Coordinatore Nazionale per l’Area Assistenza Ospedaliera presso la Commissione Salute della Conferenza Stato Regioni e membro del consiglio di amministrazione di AGENAS.

amAttilio Bianchi, Direttore Generale Istituto Nazionale Tumori
Pascale Napoli

Attilio Bianchi, 58 anni, due master in Management sanitario alla Bocconi, è stato direttore sanitario dell’ex Asl Napoli 3, Direttore dell’Azienda Sanitaria Unica delle Marche, direttore generale dell’Azienda Universitaria Ospedaliera di Salerno, e direttore generale dell’Università degli Studi di Salerno.

Antonio Postiglione, Direttore Generale per la
Tutela della Salute e il Coordinamento del Sistema
Sanitario Regionale

Fortunato Ciardiello, Professore Ordinario di Oncologia
Medica, Presidente della Scuola di Medicina e Chirurgia,
Università degli Studi della Campania Luigi Vanvitelli

amBruno Daniele, Direttore UOC Oncologia Medica AO
G. Rummo Benevento

Il Dott. Daniele è Direttore del Dipartimento Oncologico e dell'Unità Operativa Complessa di Oncologia Medica dell'A.O. G. Rummo di Benevento, sede di Centro Oncologico Regionale Polispecialistico (CORP) della Rete Oncologica.
E' membro dell'Associazione Italiana di Oncologia Medica (AIOM), dell'American Society of Clinical Oncology (ASCO), dell'European Society of Clinical Oncology (SMO), American Gastroenterological Association (AGA).
Oltre all'attività clinica, svolge attività di ricerca in particolare nell'ambito dei tumori dell'apparato gastroenterico e del fegato. Su quest'ultimo argomento ha pubblicato sulle più prestigiose riviste scientifiche ed è stato relatore a congressi nazionali e internazionali.

Sabino De Placido, Responsabile Oncologia Medica AOU
Federico II Napoli

Piera Maiolino, Responsabile Struttura Complessa Farmacia
Istituto Nazionale Tumori Pascale Napoli


amVincenzo Montesarchio, Direttore UOC Oncologia
Ospedale Monaldi Napoli

Da gennaio 2014 Coordinatore per l’A.O.R.N. dei Colli-Ospedali Monaldi- Cotugno- C.T.O. del Gruppo Multidisciplinari sui tumori neuroendocrini -ENETS Centro di eccellenza (A.O.U. Federico II- IRCCS “G. Pascale” – A.O.R.N. “A. Cardarelli” – A.O.R.N. dei Colli- Ospedali Monaldi- Cotugno- C.T.O.

Sandro Pignata, Coordinatore Scientifico Rete Oncologica
Campana

Ugo Trama, Responsabile della UOD 08 “Politica del Farmaco
e Dispositivi” presso la Direzione Generale per la Tutela della
Salute e il Coordinamento del Sistema Sanitario Regionale

Ciro Verdoliva, Direttore Generale Azienda Ospedaliera
“Antonio Cardarelli” Napoli

Valentina Orlando, Farmacoeconomista CIRFF
Federico II Napoli

Ettore Mautone, Giornalista Il Mattino

Gerardo Botti, Direttore Scientifico Istituto Nazionale Tumori
Pascale Napoli

Pellegrino Musto, Direttore Scientifico IRCCS CROB Rionero
in Vulture (PZ)

Born in 1956, Dr. Pellegrino Musto is currently Scientific Director at the Referral Cancer Center of Basilicata/Centro di Riferimento Oncologico della Basilicata” (IRCCS-CROB), an OECI recognized Clinical Cancer Center, in Rionero in Vulture (Pz), Italy (since April, 2013).

Dr. Musto received his Medical Degree “summa cum laude” from Naples University in 1982 and was Board Certified “summa cum laude” in Hematology and Medical Oncology at the Ferrara University in 1985 and 1989, respectively. Here he completed his Research Fellowship in Hematology, from 1982 to 1984.

In 1985, Dr. Musto became a Hematology staff member at the IRCCS “Casa Sollievo della Sofferenza” Hospital, in S.Giovanni Rotondo (Fg), Italy, where he progressively held the positions of Senior Assistant, responsible of the “Biology and Therapy of Chronic Hematological Malignancies” Unit and Chief of the Hematology and Day-Hospital Units until 2005.

In February, 2006, he joined the IRCCS-CROB as Director of the Unit of Hematology and Stem Cell Transplantation and Head of the Onco-Hematology Department (since 2008), until March, 2013. Dr. Musto is currently in a time-off work, due to the current role of Scientific Director in the same Institute.

He also obtained a Master in “Management of Health Services in Hematology” at the ISTUD Institute of Stresa, Italy, in 2006, and a Master in “Management of Complex Structures in National Health Service (Tor Vergata University, Rome, and Basilicata region, 2011).

Deeply interested in clinical and translational research, Dr. Musto is a frequently invited speaker and has been involved, as principal investigator or co-investigator, in a large number of national and international clinical trials on new drugs. His main interests focus on prognostic, developmental therapeutics and biological aspects of many hematological diseases including, in particular, plasma cell disorders and myelodysplastic syndromes.

He has so far published 368 articles in the field of hematologic diseases in peer-reviewed international journals covered by PubMed, including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, Blood, Leukemia, Oncogene, Clinical Cancer Research, Cancer, Bone Marrow Transplantation, Haematologica, British Journal of Haematology, and others. Of note, Dr. Musto has recently contributed to the development of international guidelines in the field of monoclonal gammopathies and multiple myeloma, within the context of’ European Myeloma Network (EMN) and of International Myeloma Working Group (IMWG). His current H-index is 56, with 11.797 citations (Scopus, May, 4, 2018; ORCID 0000-0003-3277-6594). He also authored around 500 scientific abstracts (poster or oral presentations) at national or international congresses, as well as several chapters and reviews of hematological interest.

Member, within the Italian Cooperative group GIMEMA, of Multiple Myeloma (2007-2016) and Myelodyplastic Syndromes (since 2011) Working Parties, Dr. Musto is currently member of EMN Italian Board (since 2017) and has been also involved in several other scientific Advisory Boards, as well as in Steering, Writing and Ethic Committees. He also currently coordinates or supervises several institutional research projects in hematological malignancies and has been recipient of research grants and of several financial supports from the Italian Ministry of Health and Pharmaceutical Companies .

After his election in 2009 to the Executive Board of the Italian Society of Hematology (SIE (confirmed until December, 2017), Dr. Musto was appointed Vice-President of this Society from 2010 to 2013. Starting in 2014, he is the coordinator for the development program of SIE Italian Guidelines for myelodysplastic syndromes and member of the National Committee for formative activities. From April, 2015, he is President of SIE Committee that interacts with the Italian Association of Tumor Registries (AIRTUM). In October, 2016, Dr. Musto has been elected in the Executive Board of the Italian Society of Experimental Hematology (SIES). Along with SIE and SIES, his memberships of Scientific Societies also include the American Societies of Hematology (ASH) and of Clinical Oncology (ASCO), the European Haematology Association (EHA) and AIRTUM.

Dr. Musto has served as reviewer for several international journals, such as Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Haematologica, Cancer, The Oncologist, Bone Marrow Transplantation, British Journal of Haematology, Leukemia and Lymphoma, Leukemia Research, European Journal of Haematology, Annals of Hematology, Expert Opinion Journals, and others. He is currently member of the Editorial Board of Leukemia Research and has reviewed abstracts presented at ASH, EHA, SIE, SIES and IMW meetings.

In 2011, Dr. Musto was among the founder members of the Italian Foundation of Myelodysplastic syndromes (FISM). In 2013 he became member of the Governing Council of “Alliance against Cancer” (a national association which includes all the Oncologic Scientific Institutes in Italy), and of the PhD Committee for Molecular Medicine and Pharmacology at the University of Ferrara.

On December, 2017, he received the National Scientific Qualification (MIUR) for Full Professor position (Hematology), valid until 2023.

amNico Silvestris, Direttore Scientifico Istituto Tumori
Giovanni Paolo II Bari

Since graduation, Nicola Silvestris has become involved in studies on translational research in solid tumors. In this area, he is recognized as a national and international expert, as indicated by the numerous participations in meetings and seminars as an invited speaker. From 2011 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the Italian Association of Medical Oncology (AIOM). From 2014 he has been member of the AIOM working groups dedicated to clinical research and follow up of cancer patients. From 2015, he is a Founding Member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). From 2016 he has a Lecture Position at Antwerp University, Medical School On 2017 he has been reviewer for the Cancer Research UK Clinical Research Committee of a research project.
From 2017 he is involved in the coordination of the Piano Oncologico Nazionale (years 2018-2021). Since 2017 he is collaborating with the Cancer Immunology Project and the Universal Scientific Education and Research Network. He is collaborating with Cancer Institute of Meldoa and CNR Nanotec of Lecce. He has been also charged to develop a practical proposal to organize on June 2019 the OECI Oncology Days, the main yearly event attracting the General Directors, Scientific and Medical Directors, the Pathologists and the Quality managers of the most prominent European Cancer Centres. Nicola Silvestris is also acting as main contact point to involve the Cancer Institute of Bari in the activities and projects developed by the OECI Working Groups on cancer outcomes research, supportive and palliative care, collaboration for good practices with patients. Furthermore, he is closely collaborating with OECI and he is involved in the N1 Trial Project since his developing phase. Since 2017 he is coordinating the development of the Phase I Clinical Unit of the Cancer Institute of Bari.
He has been principal investigator of more than 20 clinical trials at the Cancer institute of Bari.
Actually, he is Scientific Director pro tempore of the National Cancer Institute of Bari.
He has published more than 170 papers in peer-reviewed journals. He regularly serves as a reviewer for the most important gastroenterology journals and for funding agencies.

amAngelo Del Favero, Direttore Generale Istituto Superiore
di Sanità

Laureato in Scienze Statistiche ed Economiche dell’Università degli Studi di Padova è stato consulente del Ministro del Lavoro, della Salute e delle Politiche Sociali. È stato Direttore Generale dell’azienda ULSS della Regione Veneto e della Città della Salute della Scienza di Torino. Attualmente è Direttore Generale dell’Istituto Superiore di Sanità

Mario Braga, Coordinatore delle Attività del PNE AGENAS

Alessandro Ghirardini, Referente area Reti Cliniche e Sviluppo
Organizzativo AGENAS

amPaolo Ascierto, Direttore SC Oncologia Medica e Terapie Innovative,
IRCCS Fondazione Pascale, Napoli


Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative therapy at that same institution. He is an active Scientific Reviewer for several international journals, including, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being the Editor-in-Chief of the Combination Strategies section of the Journal of Translational Medicine, Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics, and Associate Editor of Journal of ImmunoTherapy of Cancer. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 350 national and international meetings. Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). He is also member of the Steering Committee of Society of Melanoma Research (SMR) since 2016, and member of the board of Cancer Development Drug Forum (CDDF) since 2017, as well as President of the Fondazione Melanoma Onlus since 2010, and President of Campania Society of ImmunoTherapy of Cancer (SCITO) since 2013. Professor Ascierto has presided as Principal Investigator on over 70 clinical trials and he is the author of more than 250 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research, among others. Primarily, his major research interests are the genetics and proteomics of melanoma, the assessment of molecular markers for tumour progression in melanoma, management of targeted therapies for melanoma, vaccination treatments and immunotherapy of cancer, biochemical and immunological monitoring, and combination approaches for the cancer treatment.

Vincenzo De Luca, Presidente della Regione Campania

Vai alla pagina dell’evento, clicca qui